Quince Therapeutics (QNCX) News Today $1.05 -0.04 (-3.67%) Closing price 04:00 PM EasternExtended Trading$1.04 -0.01 (-0.48%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Quince Therapeutics to Present at Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comQuince Therapeutics to Present at Jones Healthcare and Technology Innovation ConferenceApril 3, 2025 | businesswire.comQuince Therapeutics (QNCX) Expected to Announce Earnings on MondayQuince Therapeutics (NASDAQ:QNCX) will be releasing earnings before the market opens on Monday, April 7, Financial Modeling Prep reports.March 31, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 33.5% in MarchQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 1,690,000 shares, a decrease of 33.5% from the February 28th total of 2,540,000 shares. Currently, 5.2% of the shares of the company are short sold. Based on an average trading volume of 128,100 shares, the short-interest ratio is presently 13.2 days.March 30, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)March 27, 2025 | markets.businessinsider.comQuince Therapeutics (NASDAQ:QNCX) Given New $4.00 Price Target at D. Boral CapitalD. Boral Capital reduced their target price on shares of Quince Therapeutics from $12.00 to $4.00 and set a "buy" rating on the stock in a research note on Tuesday.March 26, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Releases Earnings ResultsQuince Therapeutics (NASDAQ:QNCX - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.09). The business had revenue of $0.17 million during the quarter.March 26, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Coverage Initiated by Analysts at OppenheimerOppenheimer began coverage on Quince Therapeutics in a research report on Monday. They set an "outperform" rating and a $10.00 target price on the stock.March 25, 2025 | marketbeat.comQuince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial ResultsMarch 24, 2025 | businesswire.comOppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform RecommendationMarch 24, 2025 | msn.comQuince Therapeutics (QNCX) Projected to Post Earnings on MondayQuince Therapeutics (NASDAQ:QNCX) will be releasing earnings on Monday, March 24, Financial Modeling Prep reports.March 22, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of "Buy" by AnalystsQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has earned an average recommendation of "Buy" from the six analysts that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the companMarch 18, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by BrokeragesQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating and two have given a strong buy ratingFebruary 21, 2025 | marketbeat.comQuince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-TelangiectasiaFebruary 7, 2025 | businesswire.comQuince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | businesswire.comQuince Therapeutics (NASDAQ:QNCX) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $12.00 price objective on shares of Quince Therapeutics in a research note on Wednesday.February 5, 2025 | marketbeat.comQuince Therapeutics gets USPTO notice of allowance in Ataxia-TelangiectasiaFebruary 4, 2025 | markets.businessinsider.comQuince Therapeutics secures USPTO nod for A-T treatment patentFebruary 4, 2025 | msn.comQuince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-TelangiectasiaFebruary 4, 2025 | businesswire.comQuince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-TelangiectasiaJanuary 27, 2025 | finance.yahoo.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of "Buy" by AnalystsQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has received an average rating of "Buy" from the six analysts that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the companyJanuary 27, 2025 | marketbeat.comQuince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory BoardJanuary 24, 2025 | finance.yahoo.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from AnalystsQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has earned an average rating of "Buy" from the five analysts that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the compaJanuary 2, 2025 | marketbeat.comQuince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $12.00 target price on shares of Quince Therapeutics in a report on Thursday.January 2, 2025 | marketbeat.comBrookline Capital Management Predicts QNCX FY2024 EarningsQuince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Research analysts at Brookline Capital Management issued their FY2024 earnings estimates for shares of Quince Therapeutics in a research note issued to investors on Wednesday, December 18th. Brookline Capital Management analyst K. Raja forecDecember 20, 2024 | marketbeat.comQuince Therapeutics initiated with a Buy at BrooklineDecember 19, 2024 | msn.comBrookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationDecember 19, 2024 | msn.comBrookline Capital Management Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)Brookline Capital Management started coverage on shares of Quince Therapeutics in a research note on Wednesday. They set a "buy" rating and a $9.00 price objective for the company.December 18, 2024 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short InterestQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) saw a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 2,170,000 shares, a growth of 21.2% from the November 15th total of 1,790,000 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average daily trading volume, of 548,900 shares, the days-to-cover ratio is presently 4.0 days.December 16, 2024 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest UpdateQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 1,790,000 shares, a decrease of 23.8% from the October 31st total of 2,350,000 shares. Based on an average daily volume of 527,400 shares, the days-to-cover ratio is currently 3.4 days. Approximately 5.5% of the shares of the company are short sold.November 29, 2024 | marketbeat.comQuince Therapeutics Share Price (QNCX.US)November 18, 2024 | lse.co.ukShort Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Increases By 23.0%Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,350,000 shares, an increase of 23.0% from the October 15th total of 1,910,000 shares. Based on an average trading volume of 554,300 shares, the days-to-cover ratio is presently 4.2 days. Approximately 7.3% of the company's stock are sold short.November 15, 2024 | marketbeat.comQuince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.comQuince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchNovember 13, 2024 | finance.yahoo.comQuince Therapeutics presents safety data from ATTeST trial at CNS meetingNovember 13, 2024 | markets.businessinsider.comQuince Therapeutics presents data from prior Phase 3 ATTeST clinical trialNovember 13, 2024 | markets.businessinsider.comQuince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual MeetingNovember 11, 2024 | businesswire.comQuince Therapeutics initiated with a Buy at MaximNovember 8, 2024 | markets.businessinsider.comMaxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationNovember 8, 2024 | msn.comMaxim Group Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)Maxim Group initiated coverage on shares of Quince Therapeutics in a research report on Thursday. They issued a "buy" rating and a $6.00 price objective for the company.November 7, 2024 | marketbeat.comQuince Therapeutics initiated with a Buy at Rodman & RenshawOctober 30, 2024 | markets.businessinsider.comQuince Therapeutics (NASDAQ:QNCX) Upgraded at RODMAN&RENSHAWRODMAN&RENSHAW raised shares of Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday.October 30, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationOctober 30, 2024 | msn.comEF Hutton Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationOctober 22, 2024 | msn.comQuince Therapeutics to Participate at Upcoming Investor ConferencesOctober 14, 2024 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 SharesSeptember 4, 2024 | insidertrades.comQuince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comQNCX Quince Therapeutics, Inc.August 30, 2024 | seekingalpha.comQuince Therapeutics, Inc. (NASDAQ:QNCX) President Charles S. Ryan Acquires 48,387 SharesAugust 23, 2024 | insidertrades.comQuince Therapeutics, Inc. (NASDAQ:QNCX) COO Brendan Hannah Acquires 30,845 SharesAugust 22, 2024 | insidertrades.com Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address QNCX Media Mentions By Week QNCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNCX News Sentiment▼0.000.69▲Average Medical News Sentiment QNCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNCX Articles This Week▼11▲QNCX Articles Average Week Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Gossamer Bio News DiaMedica Therapeutics News Inventiva News MediWound News Eledon Pharmaceuticals News Cardiff Oncology News Voyager Therapeutics News Alumis News Fulcrum Therapeutics News Y-mAbs Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNCX) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QNCX Stock Free QNCX Stock Alerts